In WHO grade IV GBM, IDH mutation has been repeatedly shown to be predictive of improved response to temozolomide treatment and radiotherapy in secondary GBM malignancies that have transformed from lower grade gliomas [39,40]. The gene discussed is IDH2; the disease is glioblastoma.